5-Jod-2'-deoxyuridin | 25954-19-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-Jod-2'-deoxyuridin
• 英文别名: 5'-iododeoxyuridine；5'-iodo-2'-deoxyuridine；1-[(2R,4S,5S)-4-hydroxy-5-[hydroxy(iodo)methyl]oxolan-2-yl]pyrimidine-2,4-dione
• CAS: 25954-19-2
• 化学式: C₉H₁₁IN₂O₅
• 分子量: 354.101
• InChiKey: PJRXFSIYFLCCEH-XKBRQERYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  99.1
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS<br/>[FR] COMBINAISONS ET RÉGIMES POSOLOGIQUES POUR TRAITER DES TUMEURS RB-POSITIVES
  申请人：G1 THERAPEUTICS INC

  公开号：WO2016040858A1

  公开（公告）日：2016-03-17

  This invention directed to methods for treating select RB-positive cancers and other Rb- positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with another chemotherapeutic, for example, an additional kinase inhibitor, PD-1 inhibitor, or BCL-2 inhibitor, or combination thereof.

  这项发明涉及使用特定剂量和组合或交替方案中的CDK4/6抑制剂治疗选择性RB阳性癌症和其他RB阳性异常细胞增殖紊乱疾病的方法。在一个方面，揭示了使用特定CDK4/6抑制剂与另一种化疗药物（例如，额外的激酶抑制剂、PD-1抑制剂或BCL-2抑制剂，或其组合）组合或交替治疗选择性RB阳性癌症。
• [EN] GEL FORMULATIONS FOR ENHANCING THE EFFECT OF RADIOTHERAPY<br/>[FR] FORMULATIONS DE GEL POUR AMÉLIORER L'EFFET DE RADIOTHÉRAPIE
  申请人：UNIV DENMARK TECH DTU

  公开号：WO2016079331A1

  公开（公告）日：2016-05-26

  The present invention relates to a composition comprising: a. non-water soluble carbohydrates b. a contrast agent for imaging, wherein at least 60% of the contrast agent remains within 10 cm from the injection site after 24h, for use in local co-administration into a human or animal body, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration.

  本发明涉及一种包含以下成分的组成物：a. 非水溶性碳水化合物 b. 成像的对比剂，其中至少60%的对比剂在24小时后保持在注射部位10厘米范围内，用于在人体或动物体内局部共同给药，并且该组成物在给药前为液态，在给药后在粘度上增加超过1,000厘泊（cP）。
• NUCLEIC ACID BINDING DYES AND USES THEREFOR
  申请人：McDougall Mark

  公开号：US20100233710A1

  公开（公告）日：2010-09-16

  The invention provides novel compounds and compositions of Formulas I and II, as well as methods of using them. The compounds can be used, for example, to quantify an amount of double stranded DNA in a sample subjected to nucleic acid amplification, or for real time monitoring of a nucleic acid amplification reaction. The compounds can be provided in a kit, for example, with other reagents and instructions for using the compounds and reagents.

  这项发明提供了Formula I和Formula II的新化合物和组合物，以及使用它们的方法。这些化合物可以用于例如，在经过核酸扩增的样本中定量双链DNA的数量，或者用于实时监测核酸扩增反应。这些化合物可以作为一种试剂盒的一部分提供，例如，与其他试剂和使用这些化合物和试剂的说明书一起。
• [EN] SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF<br/>[FR] PETITES MOLÉCULES INHIBITRICES DE MCL-1 ET LEURS UTILISATIONS
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2016172218A1

  公开（公告）日：2016-10-27

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having benzoic acid structure which function as inhibitors of Mcl-1 protein, and their use as therapeutics for the treatment of cancer and other diseases.

  这项发明属于药物化学领域。具体来说，该发明涉及一类具有苯甲酸结构的新型小分子，其作为Mcl-1蛋白的抑制剂，并且它们作为治疗癌症和其他疾病的药物的用途。
• [EN] SMALL MOLECULE INDUCERS OF REACTIVE OXYGEN SPECIES AND INHIBITORS OF MITOCHONDRIAL ACTIVITY<br/>[FR] INDUCTEURS DE PETITES MOLÉCULES DE DÉRIVES RÉACTIFS DE L'OXYGÈNE ET INHIBITEURS DE L'ACTIVITÉ MITOCHONDRIALE
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2017155991A1

  公开（公告）日：2017-09-14

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazolinedione structure which function as reactive oxygen species (ROS) inducers and inhibitors of mitochondrial activity within cancer cells (e.g., pancreatic cancer cells), and their use as therapeutics for the treatment of cancer (e.g., pancreatic cancer) and other diseases.

  这项发明属于药物化学领域。具体来说，该发明涉及一类具有喹唑啉二酮结构的小分子，其作为活性氧（ROS）诱导剂和对癌细胞（例如胰腺癌细胞）内线粒体活性的抑制剂，并将它们用作治疗癌症（例如胰腺癌）和其他疾病的药物。